SKIN

In the past six months, SkinHealth Systems' stock has been affected by several events. The company rebranded in April 2026, aiming for a clinically driven platform. The Q1 2026 earnings report in May 2026 showed net sales of $64.9 million, a 6.7% year-over-year decrease, but adjusted EBITDA rose 17% to $8.5 million. The company lowered its full-year 2026 net sales guidance but maintained its adjusted EBITDA guidance. Three new independent directors were appointed to the Board in April/May 2026. The stock price has been volatile, declining 24.27% over the past year as of May 1, 2026.